Kurzfassung

The planned studies will investigate whether sanguinarine in combination with cabozantinib inhibits the progressive growth behavior of renal cell carcinoma (RCC) in a synergistic or additive manner. Alterations in cell cycle dysregulation and cell death induction as well as modulation of proteins involved will be evaluated. The objective is to determine if and to what extent sanguinarine supports guideline-directed therapy with cabozantinib in RCC cells and to identify the underlying...The planned studies will investigate whether sanguinarine in combination with cabozantinib inhibits the progressive growth behavior of renal cell carcinoma (RCC) in a synergistic or additive manner. Alterations in cell cycle dysregulation and cell death induction as well as modulation of proteins involved will be evaluated. The objective is to determine if and to what extent sanguinarine supports guideline-directed therapy with cabozantinib in RCC cells and to identify the underlying mechanisms. The long-term goal is to provide a more effective treatment option for patients with advanced RCC.» weiterlesen» einklappen